Sarcopenia in rheumatoid arthritis: Is it a common manifestation?

Tekgöz, Emre; Çolak, Seda; Ateş, Funda Seher Özalp; Sonaeren, I.; Yılmaz, Sedat; Çınar, Muhammet

doi:10.1111/1756-185x.13976

Cited by 17 publications

(23 citation statements)

References 39 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sarcopenia in RA is a common manifestation and occurs significantly more frequently than in healthy controls. 8 32 According to the updated EWGSOP2 guideline, we found a prevalence of a confirmed sarcopenia in 4.5% of patients with RA and 0.4% of controls without a difference in sex. This means the prevalence of sarcopenia was 11 times higher in patients with RA compared with the control group.…”

Section: Discussionmentioning

confidence: 79%

“…4 5 In rheumatoid arthritis (RA), the prevalence of sarcopenia was found to be increased compared with healthy peers. [6][7][8][9][10] As a manifestation of an altered body composition, Giles et al observed the reduction of lean mass in patients with RA, while fat mass remained constant or even increased. 11 Presumably, this process is triggered by augmented circulating inflammatory cytokines, like TNF-α and Interleukin 1β, causing an intensified metabolism as well as an increasing peripheral insulin resistance.…”

Section: What Is Already Known On This Topicmentioning

confidence: 99%

“…In rheumatoid arthritis (RA), the prevalence of sarcopenia was found to be increased compared with healthy peers 6–10. As a manifestation of an altered body composition, Giles et al observed the reduction of lean mass in patients with RA, while fat mass remained constant or even increased 11.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition

et al. 2022

View full text Add to dashboard Cite

ObjectiveIn rheumatoid arthritis (RA), chronic inflammation can enhance the development of sarcopenia with a depletion of muscle mass, strength and performance. Currently, a consensus definition for sarcopenia and solid results for the prevalence of sarcopenia in patients with RA are lacking.MethodsIn this cross-sectional study, 289 patients ≥18 years with RA were recruited. Dual X-ray absorptiometry was performed to measure appendicular lean mass. Assessment of muscle function included grip strength, gait speed and chair rise time. Prevalence of sarcopenia was defined using the updated European Working Group on Sarcopenia in Older People (EWGSOP2) and the Foundation for the National Institutes of Health (FNIH) definition. In addition, the RA study population was compared with existing data of healthy controls (n=280).Results4.5% of patients (59.4±11.3 years) and 0.4% of controls (62.9±11.9 years) were affected by sarcopenia according to the EWGSOP2 definition. Body weight (OR 0.92, 95% CI 0.86 to 0.97), body mass index (BMI) (OR 0.70, 95% CI 0.57 to 0.87), C reactive protein (CRP) (OR 1.05, 95% CI 1.01 to 1.10), disease duration (OR 1.08, 95% CI 1.02 to 1.36), current medication with glucocorticoids (OR 5.25, 95% CI 2.14 to 24.18), cumulative dose of prednisone equivalent (OR 1.04, 95% CI 1.02 to 1.05) and Health Assessment Questionnaire (HAQ) (OR 2.50, 95% CI 1.27 to 4.86) were associated with sarcopenia in patients with RA. In contrast, the prevalence was 2.8% in patients compared with 0.7% in controls when applying the FNIH definition, and body height (OR 0.75, 95% CI 0.64 to 0.88), BMI (OR 1.20, 95% CI 1.02 to 1.41), CRP (OR 1.06, 95% CI 1.01 to 1.11) and HAQ (OR 2.77, 95% CI 1.17 to 6.59) were associated with sarcopenia.ConclusionSarcopenia is significantly more common in patients with RA compared with controls using the EWGSOP2 criteria. The FNIH definition revealed sarcopenia in individuals with high BMI and fat mass, regardless of the presence of RA.Trial registration numberIt was registered at the German Clinical Trials Registry (DRKS) as well as WHO Clinical Trials Registry (ICTRP) (DRKS00011873, registered on 16 March 2017).

show abstract

Section: Discussionmentioning

confidence: 79%

Section: What Is Already Known On This Topicmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Out findings corroborate the previous results indicating that patients with a long disease duration tend to have a relatively low muscle mass and are expected to experience little increase in muscle mass from treatment relative to their counterparts who have a short disease duration. 7,10,49,50 Although this meta-analysis furnished promising evidence, the evidence should be interpreted in light of the present study's limitations. First, due to varieties of exercise regimes used in the included studies, we could not determine the effect of a specific type of exercise on muscle mass gain.…”

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Exercise therapy for sarcopenia in rheumatoid arthritis: A meta-analysis and meta-regression of randomized controlled trials

et al. 2021

View full text Add to dashboard Cite

Objective: Rheumatoid arthritis and age are associated with high sarcopenia risk. Exercise is an effective treatment for preventing muscle mass loss in older adult populations. It remains unclear whether exercise affects muscle mass in people with rheumatoid arthritis. Thus, this meta-analysis investigated the effect of exercise on muscle mass gain in patients with rheumatoid arthritis. Data sources: PubMed, EMBASE, the Cochrane Library, the Physiotherapy Evidence Database (PEDro), the China Knowledge Resource Integrated Database, and Google Scholar were systematically searched until June 2021. Methods: The present study was conducted according to the guidelines recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Randomized controlled trials (RCTs) that reported the effects of exercise on muscle mass for rheumatoid arthritis were identified. The included RCTs were subject to meta-analysis and risk of bias assessment. Subgroup and random-effects meta-regression analyses were performed to identify any heterogeneity ( I2) of treatment effects across studies. Results: We included nine RCTs with a median PEDro score of 6/10 (range: 4/10–8/10). The weighted mean effect size for muscle mass was 0.77 (95% CI: 0.30–1.24; P = 0.001; I2 = 77%). Meta-regression analyses indicated that the disease duration significantly explained variance of treatment effects across studies (β = −0.006, R2 = 69.7%, P = 0.005). Conclusions: Exercise therapy effectively increased muscle mass in patients with rheumatoid arthritis. Treatment effects may be attenuated in those who have had rheumatoid arthritis for a relatively long time.

show abstract

Obesity, sarcopenia, and arthritis and the theory of relativity: comment on the article by Baker et al

Santiago

Rosa

Moura

2023

Arthritis Care & Research

View full text Add to dashboard Cite

Sarcopenia in rheumatoid arthritis: Is it a common manifestation?

Cited by 17 publications

References 39 publications

Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition

Prevalence of sarcopenia in patients with rheumatoid arthritis using the revised EWGSOP2 and the FNIH definition

Exercise therapy for sarcopenia in rheumatoid arthritis: A meta-analysis and meta-regression of randomized controlled trials

Obesity, sarcopenia, and arthritis and the theory of relativity: comment on the article by Baker et al

Contact Info

Product

Resources

About